Tested Applications
| Positive IHC detected in | rat brain tissue, mouse brain tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
20721-1-AP targets OTOF in IHC, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | otoferlin |
| Calculated Molecular Weight | 227 kDa |
| GenBank Accession Number | NM_004802 |
| Gene Symbol | OTOF |
| Gene ID (NCBI) | 9381 |
| RRID | AB_3085618 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9HC10 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
Otoferlin, a C2 domain transmembrane protein, is a major calcium sensor regulating extracellular secretion in mammalian internal hair cells. Deafness caused by mutations in the OTOF gene encoding Otoferlin is a recessive genetic disorder, a sensorineural deafness. It is expressed in the brain, inner hair cells and vestibular hair cells.(PMID: 17055430; PMID: 17229086)
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for OTOF antibody 20721-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The OTOF Polyclonal antibody (Cat# 20721-1-AP) has 1 citation to date. It appears in Cancers (Basel) (Impact Factor 4.8), published in 2026. The cited study investigates OTOF's role in promoting clear cell renal cell carcinoma progression and angiogenesis through AKT-dependent HIF/VEGFA signaling, placing the research in the fields of cancer biology, tumor angiogenesis, and intracellular signaling pathways.
| Species | Application | Title |
|---|---|---|
Cancers (Basel) OTOF Promotes Clear Cell Renal Cell Carcinoma Progression and Angiogenesis Through AKT-Dependent HIF/VEGFA Signaling. |







